Reveal Genomics and Ona link on ONA-255 development for cancer
Pharmaceutical Technology
APRIL 15, 2025
Reveal Genomics and Ona Therapeutics have entered a strategic partnership to expedite the clinical development of ONA-255.
The use of genomic profiling testing to improve oncology care
pharmaphorum
SEPTEMBER 12, 2022
Alongside drugs and therapeutics, data collection and technology enhancements have redefined the traditional healthcare experience, especially within oncology, and genomic profiling has become a significant factor in allowing for personalised care. Tailored oncology.
Genome 
105
105 Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Leveraging Genetic Testing for Enrolling Rare Disease Trials
Worldwide Clinical Trials
JANUARY 24, 2024
Newborn Sequencing is a research initiative that allows for a baby’s full genome to be sequenced at birth, diagnosing their genetic diseases. Genetic counselors are critical in this pathway, especially as more is learned about the human genome and relevant incidental findings.
Genetics 189
189 
Precision Signs Another Collab for ARCUS Genome Editing Platform
BioSpace
SEPTEMBER 8, 2021
based Precision BioSciences announced a license and collaboration deal with Philadelphia-based iECURE and described its clinical development plans. Durham, N.C.-based
Genome 70
70 
Canine cancer research startup impacts treatment in humans
Outsourcing Pharma
APRIL 19, 2021
One Healthâs FidoCure is using genomics and AI technology to develop precision oncological treatments, and the work is benefiting human cancer research.
Research 115
115 
Cancer detection tech uses AI, whole-genome sequencing
Outsourcing Pharma
APRIL 22, 2021
An advanced cancer detection platform from C2i Genomics (reportedly capable of spotting miniscule traces of the disease) recently landed $100m in funding.
Genome 52
52 
Bluestar Genomics Closes $70M Series C Funding, Expands Scientific Advisory Board
BioTech 365
MAY 12, 2021
Bluestar Genomics Closes $70M Series C Funding, Expands Scientific Advisory Board Bluestar Genomics Closes $70M Series C Funding, Expands Scientific Advisory Board Additional Funding and Scientific Expertise Advance Company’s Clinical Development and Efforts Towards Commercialization SAN DIEGO–(BUSINESS WIRE)–Bluestar Genomics, an … (..)
Genome 40
40 
Pharma’s spend on AI in drug discovery ‘could top $3bn by 2025’
pharmaphorum
JULY 8, 2022
The aim is to overcome a very low success rate in drug discovery, with just 10% of candidates making it into clinical development despite the application of new computational technology techniques to handle an ever-growing amount of biomedical data, for example from genomics studies. billion, according to the report.
Drugs 131
131 
The power of R&D collaborations to improve outcomes in rare diseases
pharmaphorum
OCTOBER 7, 2021
However, developments in genomic medicine are making huge strides to improve this situation, and these will also be discussed during the webinar. His academic and clinical focus is on benign haematology, where he has a particular interest in sickle cell disease, haemophilia and other rare blood disorders.
Genome 98
98 
Movers and shakers: New appointments in pharma industry - Transgene, CN Bio and more
BioPharma Reporter
FEBRUARY 8, 2024
Enhanc3D Genomics, Cytomos and Cellular Origins are among the companies welcoming new faces to top jobs. Outsourcing Pharma and BioPharma Reporter breaks down the key people on the move in the pharma industry.
Genome 105
105 
Paradigm4, 54gene collaborate on African clinical data
Outsourcing Pharma
JANUARY 26, 2021
With fewer than 3% of analyzed genomes currently coming from Africans, the companies are looking to increase access to and understanding of patient data.
Genome 94
94 
To Share or Not to Share Failed Genetic Screening Results with Patients
Worldwide Clinical Trials
FEBRUARY 6, 2023
When using genetic screening to identify clinical trial volunteers, a sponsor’s obligations for further testing and disclosure of results to patients and families are unclear, especially when the results have no impact on medical management. Guidance in this area is much needed.
Genetics 130
130 
SOPHiA GENETICS and AstraZeneca partner for oncology drugs development
Pharmaceutical Technology
FEBRUARY 13, 2023
The company expects that its platform and multimodal capabilities will lead to a new era of precision oncology by improving early diagnosis and patient identification, accelerating innovative medicines adoption along the care pathway and optimising clinical development.
Genetics 130
130 
Scioto Biosciences Receives Series B Investment from Genome & Company
BioTech 365
AUGUST 11, 2020
Funding will be used to support ongoing clinical development of Scioto’s lead product, SB-121, as a microbiome treatment for diseases affecting the gut-brain axis and gut injury INDIANAPOLIS–(BUSINESS WIRE)–Scioto Biosciences announced today the closing of a strategic investment of up … Continue reading →
Genome 40
40 
GSK and Wave Life Sciences partner to develop oligonucleotide therapeutics
Pharmaceutical Technology
DECEMBER 14, 2022
GSK has entered a strategic partnership with Wave Life Sciences to progress the discovery and development of oligonucleotide therapies for new genetic targets. The alliance will merge the PRISM oligonucleotide platform of Wave and the capabilities of GSK in genetics and genomics.
Life Science 162
162 
Medable, Seqster pair up on real-world data for remote trials
pharmaphorum
MARCH 2, 2021
Decentralised studies reduce or eliminate the need to travel to clinical sites, and the two partners want to go even further by harnessing technologies that can provide additional data in real-time to generate “a more holistic view of patient health,” according to Medable CEO Dr Michelle Longmire.
Trials 98
98 
IBM sells off large parts of Watson Health business
pharmaphorum
JANUARY 24, 2022
Francisco Partners is picking up a range of databases and analytics tools – including Health Insights, MarketScan, Clinical Development, Social Programme Management, Micromedex and other imaging and radiology tools – for an undisclosed sum estimated to be in the region of $1 billion.
Radiology 111
111 
Celltrion develops tailored neutralising antibody cocktail treatment with CT-P59 to tackle COVID-19 variant spread using its antibody development platform
Drug Discovery Today
FEBRUARY 16, 2021
CT-P59 demonstrated neutralising capability against key emerging mutations, including the UK variant in addition to six variant genome mutations of SARS-CoV-2. Celltrion has constructed a COVID-19 antibody portfolio and clinical development platform to help combat the spread of the virus mutations
Antibody 45
45 
Movers and shakers: New appointments in pharma industry - Transgene, CN Bio and more
BioPharma Reporter
FEBRUARY 8, 2024
Enhanc3D Genomics, Cytomos and Cellular Origins are among the companies welcoming new faces to top jobs. Outsourcing Pharma and BioPharma Reporter breaks down the key people on the move in the pharma industry.
Genome 59
59 
Innovations in mass spectrometry accelerate the shift toward precision medicine
BioPharma Reporter
OCTOBER 22, 2024
Thermo Fisherâs John Lesica discusses how mass spectrometry technology enables scientific breakthroughs in genomics and proteomics to provide valuable insights for drug discovery and development.
Medicine 52
52 
Sanofi wagers $400m on miRecule muscular dystrophy therapy
pharmaphorum
OCTOBER 5, 2022
.” The partners are still in the discovery stage of the collaboration, and Sanofi will take full responsibility for the programme once a drug candidate to take forward into preclinical and clinical testing has been selected. The aim will be to identify promising candidates in areas of “unmet patient need.”
RNA 105
105 
UCB revs up its gene therapy drive with Handl acquisition
pharmaphorum
NOVEMBER 12, 2020
In 2018, it bought Element Genomics – a spin-out of Duke University in the US – to add genome-editing technologies, and has also been growing its internal exercise at its Boston R&D hub, although so far it hasn’t advanced and gene therapies into clinical development.
Gene Therapy 52
52 
Boehringer Ingelheim and Lifebit announce partnership to capture transformational value of health data
The Pharma Data
MARCH 1, 2022
A key element of this partnership involves Lifebit’s CloudOS platform – a powerful, secure and cutting-edge platform used by a growing number of research organizations and governments globally, such as Genomics England and The Hong Kong Genome Project.
Biobanking 52
52 
?5 Things You Need to Know from Our Recent Gene Therapy Webinar
Worldwide Clinical Trials
JUNE 15, 2022
It really is—there has been a 10x increase in cell and gene therapies in the clinical development pipeline since 2012. Most of this pipeline focuses on oncology and rare disease investigational therapeutics, and most, unsurprisingly, are in the earlier phases of development. The cell and gene therapy pipeline is booming.
Gene Therapy 130
130 
EdiGene Expands Management Team by Appointment of Head of US Subsidiary Dr. Bo Zhang and Head of Business Development Dr. Kehua Fan
The Pharma Data
DECEMBER 13, 2020
which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, today announced the appointment of Bo Zhang, Ph.D., as Head of Business Development. 14, 2020 10:00 UTC. BEIJING & CAMBRIDGE, Mass.–( He received his B.S.
Bayer’s Vividion unit forges $930m cancer alliance with Tavros
pharmaphorum
OCTOBER 13, 2022
million in future payments tied to preclinical, clinical development, and commercial achievements. Bayer bought Vividion for $1.5 Vividion is making an upfront payment of $17.5 million to get the collaboration underway, with the objective of finding four targets that could generate another $430.5
Gene Therapy 64
64 
Intellia Gets FDA Clearance to Start First Ever Phase III Trial for an In Vivo CRISPR Drug
XTalks
OCTOBER 20, 2023
Clinical-stage genome editing company Intellia Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to start a pivotal phase III trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy.
In-Vivo 52
52 
Bayer receives approval for Vitrakvi™ in Japan
The Pharma Data
MARCH 23, 2021
The marketing authorization of Vitrakvi follows the approval of the expanded use of FoundationOne ® CDx, a comprehensive genomic profiling (CGP) test, in Japan for use as a companion diagnostic (CDx) to identify patients with TRK fusion cancer who are expected to benefit from treatment with Vitrakvi. Fields, M.D., About Oncology at Bayer.
Genome 52
52 
KSQ Therapeutics and Takeda Enter Broad Strategic Collaboration to Research, Develop and Commercialize Novel Immuno-Oncology Therapies
The Pharma Data
JANUARY 12, 2021
KSQ and Takeda can collaborate on IND-enabling activities, with clinical development led by Takeda to explore multiple modalities. Takeda will assume responsibility for funding all development and commercialization activities. KSQ is also eligible to receive tiered royalties on net sales of each approved product.
Development 52
52 
BMS joins forces with insitro to develop neurodegenerative treatments
pharmaphorum
OCTOBER 29, 2020
The platform applies machine learning, human genetics, and functional genomics to generate predictive in vitro models that provide insights into disease progression. BMS will have the option to select targets identified by insitro and then lead clinical development.
Development 45
45 
ADARx Raises $75M Series B; Fast Track Designation for Vor Biopharma’s drug; Ixaka’s cell therapy clears phase 3; Breakthrough Device Designation to NovoTTF-200T™ System
Delveinsight
SEPTEMBER 14, 2021
VOR33 comprises CRISPR genome-edited hematopoietic stem and progenitor cells , which have been engineered to exclude CD33. Once infused, VOR33 is developed to protect patients’ healthy cells from anti-CD33 therapies , such as VCAR33 or Mylotarg (gemtuzumab ozogamicin). Ixaka remains blinded to the data until the execution of the trial.
RNA 67
67 
Monte Rosa Therapeutics raises $96m to develop protein-degrading molecules
The Pharma Data
SEPTEMBER 25, 2020
The new funding will be used to accelerate the development of Monte Rosa’s pipeline, advance products into clinical testing and bolster its platform capability to design and develop precision medicines for genomically defined diseases with limited treatment options. “We Source link.
Protein 40
40 
ASCO 2023: Summit Therapeutics plans to rise with bispecific NSCLC data
Pharmaceutical Technology
JUNE 5, 2023
This latest release features data from 135 patients in the first cohort of the Phase II study, (NCT04736823), which enrolled those who are treatment-naïve with advanced or metastatic NSCLC whose tumours do not have actionable genomic alterations. months for the overall cohort.
Genome 130
130 
LogicBio Therapeutics Receives FDA Fast Track Designation for LB-001 for the Treatment of Methylmalonic Acidemia (MMA)
The Pharma Data
NOVEMBER 3, 2020
According to the FDA, the purpose of Fast Track designation is to get important new drugs to patients earlier by facilitating the development, and expediting the review, of drugs to treat serious conditions and fill an unmet medical need. Commenting on the announcement, Daniel Gruskin, M.D., LogicBio is headquartered in Lexington, Mass.
BioSpace Movers & Shakers, Nov. 6
The Pharma Data
NOVEMBER 5, 2020
Taveras will lead all research and non-clinical development functions supporting the company’s pipeline of investigational therapies. Deep Genomics – Toronto-based Deep Genomics appointed Amanda Kay to the newly-created role of chief business officer. Before GSK, Rosén was senior vice president, U.S.
Genome 40
40 
Joined up thinking needed for joined up data plans
pharmaphorum
MAY 19, 2022
It was, they explained, stakeholders from across the healthcare ecosystem coming together to share insights, whether from clinic, research, or genomics, that changed the course of the COVID-19 pandemic.
Genome 52
52 
IWD: Spotlight on women in life sciences
pharmaphorum
MARCH 8, 2022
DI: Oncology is a hugely exciting area at the moment, particularly the further focus on genome testing to help identify specific mutations in the DNA and select the best treatment option for the patient and their type of cancer. Avideh Nazeri is vice president clinical development, medical, and regulatory affairs, Novo Nordisk UK.
Life Science 98
98 
Lumos Pharma’s Commitment to Innovation in Rare Pediatric Growth Disorders
XTalks
MAY 23, 2024
“We believe that our proactive engagement will pave the way for a streamlined and efficient development process, thereby expediting access to innovative treatments for patients with this condition,” he says. Advancements in genomic technology, precision medicine and gene therapy offer hope for personalized treatments and improved outcomes.
Winship Cancer Institute of Emory University Joins Caris’ Precision Oncology Alliance
The Pharma Data
OCTOBER 19, 2020
By leveraging the comprehensive genomic, transcriptomic and proteomic profiling available through the Caris Molecular Intelligence® platform, physicians from Winship will be able to further prioritize therapeutic options and determine which clinical trial opportunities may benefit their patients.
Life Science 52
52 
Regulatory Trends in Cell and Gene Therapies
Advarra
NOVEMBER 29, 2022
Bottlenecks in the manufacturing process, supply chain issues such as accessibility of good manufacturing practice (GMP)-grade reagents, and shortages of qualified scientists and engineers have caused many therapies to fail at critical stages of the clinical development pipeline.
Gene Therapy 52
52 
New research across its oncology portfolio at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021
The Pharma Data
APRIL 6, 2021
and European Union (EU) approvals, will also be presented, including long-term outcomes in patients with TRK fusion cancer receiving larotrectinib and data from the 100,000 Genomes Project analyzing the prognostic factor for survival for patients with tumors that harbor a neurotrophic receptor tyrosine kinase ( NTRK ) gene fusion.
Research 52
52 
Advances in Genetic Medicine May Be Outpacing Some Clinicians’ Understanding, But Pharmaceutical Marketers Can Do Much to Address the Problem
Pharma Marketing Network
DECEMBER 21, 2020
Almost two decades after the human genome was sequenced, a trickle of new genetic medicines (i.e., those that modify the expression of an individual’s genes or repair abnormal genes) has entered clinical practice, including 11 RNA therapeutics, 2 in vivo gene therapies, and 2 gene-modified cell therapies.
Genetics 52
52 
Enhancing Lupus Clinical Trials with Real-World Data Sources
XTalks
JANUARY 17, 2024
Why should companies consider accessing RWD for their solution development? Frederico Calado: Companies should use RWD throughout the drug lifecycle, starting with informing clinical development plans. These databases also typically miss critical information like genomic and molecular data.
Datopotamab Deruxtecan Combinations Showed Encouraging TumorResponses in Patients with Advanced Non-Small Cell Lung Cancer inTROPION-Lung02 Phase 1b trial
The Pharma Data
JUNE 7, 2023
Results will be presented on June 6 during an oral presentation (#9004) at the American Society of Clinical Oncology Annual Meeting (#ASCO23). Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) being jointly developed by Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN). “We
Trials 40
40 
Let's personalize your content